Skip to main
VKTX

Viking Therapeutics (VKTX) Stock Forecast & Price Target

Viking Therapeutics (VKTX) Analyst Ratings

Based on 14 analyst ratings
Buy
Strong Buy 50%
Buy 36%
Hold 14%
Sell 0%
Strong Sell 0%

Bulls say

Viking Therapeutics Inc. is strategically positioned to enhance its clinical updates and strategic options, which could positively influence sentiment leading up to significant clinical readouts. The company stands out among independent late-stage metabolic developers, benefiting from a scarcity premium as the competitive landscape becomes more concentrated, further highlighting its maturity and strong data capabilities. With promising clinical candidates like VK2735 and an upcoming amylin agonist IND, Viking is well-equipped to attract favorable partnerships and financing, potentially improving its market presence in the expanding metabolic disorders sector.

Bears say

Viking Therapeutics Inc. operates within a highly competitive and unpredictable biotechnology sector, which presents numerous risks such as unexpected clinical outcomes and regulatory hurdles that can significantly impact its financial prospects. Additionally, the company faces challenges related to the complex and price-sensitive nature of commercial markets for its product candidates, potentially limiting revenue generation and profitability. The increased scrutiny over licensing deals, particularly in the context of US-China relations, further compounds the uncertainties surrounding Viking's strategic partnerships and market opportunities.

Viking Therapeutics (VKTX) has been analyzed by 14 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 36% recommend Buy, 14% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Viking Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Viking Therapeutics (VKTX) Forecast

Analysts have given Viking Therapeutics (VKTX) a Buy based on their latest research and market trends.

According to 14 analysts, Viking Therapeutics (VKTX) has a Buy consensus rating as of Feb 4, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $87.07, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $87.07, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Viking Therapeutics (VKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.